Phase III results show rituximab excels against pediatric Burkitt lymphoma
(University of Colorado Anschutz Medical Campus) Results of the phase III Inter-B-NHL-ritux 2010 clinical trial reported today in the New England Journal of Medicine show 95 percent three-year survival for pediatric patients with advanced B-cell non-Hodgkin lymphoma treated with the addition of anti-cancer immunotherapy rituximab to standard chemotherapy.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
More News: Burkitt Lymphoma | Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | Immunotherapy | International Medicine & Public Health | Lymphoma | Non-Hodgkin's Lymphoma | Pediatrics | Rituxan